Noxopharm (ASX:NOX) has announced that research from its inflammation-related Sofra preclinical program will be presented orally at the upcoming 15th International Congress on Systemic Lupus Erythematosus (LUPUS 2023).
The event will be held in Seoul in May and will feature a large audience of more than 2,000 international participants, including world-renowned experts in autoimmune diseases.
The company said the abstract will also be published in Lupus Science & Medicine, the official journal of the Lupus Foundation of America.
The abstract has been selected by an expert committee for oral presentation to showcase the results from Noxopharm’s proprietary new class of therapeutics, which are demonstrating promising activity against autoimmune diseases such as lupus.
The Sofra technology platform is based on in-licensed technology from Melbourne’s Hudson Institute of Medical Research via Noxopharm’s Pharmorage subsidiary.
Noxopharm said that, unlike other anti-inflammatory drugs that target the end-stages of the inflammatory process, its short nucleic acid sequences, known as oligonucleotides, allow the inflammation to be blocked at its source.
Noxopharm CEO Dr Gisela Mautner said, “To be recognised at such a high-profile conference is a great outcome that reflects the promising nature of the Sofra platform. We are working in close collaboration with the Hudson Institute team on these novel therapeutics, and believe that our findings will receive considerable attention from scientists and other biotech companies. There is growing interest in the potential of oligonucleotides to open up new pathways to treatments for a wide range of diseases, and numerous industry participants are looking to complement or add to their existing portfolios as the technology continues to evolve.”
